The upregulation of SGLT1 in myocardial cells of HF patients had been observed in previous studies, and the modulation of SGLT1 might benefit in reversing cardiac remodeling and improving pumping function in HF patients.[33,34] Although the plausible explanation may help to illustrate the reason for more CV benefits of low SGLT2/SGLT1 selectivity inhibitors in HF patients, more studies are needed to examine the hypothesis. Here, SLC5A1 is linked to hydrops fetalis.